Pfizer exec jumps ship to join Biogen

1 August 2017

Anabella Villalobos has been appointed as senior vice president, Biotherapeutic & Medicinal Sciences (BTMS), at US biotech major Biogen (Nasdaq: BIIB).

Dr Villalobos will lead Biogen’s BTMS organization in the delivery of high-quality, differentiated molecules to the clinic. She will report to Michael Ehlers, executive vice president, head of research and development.

Dr Villalobos joins Biogen from Pfizer (NYSE: PFE) Worldwide Research and Development, where she most recently served as vice president and head of medicinal synthesis technologies. With over 25 years of industry experience in the areas of neuroscience and medicinal chemistry, she has been instrumental in the development of clinical candidates for Alzheimer’s disease, Parkinson’s disease, schizophrenia and pain.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK